Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Neurocrine Biosciences, Inc. (NBIX) had Cost of Goods Sold of $13.80M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$814.50M |
|
$197.90M |
|
|
Cost of Goods Sold |
$13.80M |
$800.70M |
|
$621.10M |
|
$193.40M |
|
$53.40M |
|
$246.80M |
|
$221.50M |
|
$197.90M |
|
$197.90M |
|
$197.90M |
|
$167.59M |
|
$193.40M |
|
$200.70M |
|
100.50M |
|
103.40M |
|
$1.97 |
|
$1.91 |
|
| Balance Sheet Financials | |
$2.44B |
|
$90.90M |
|
$2.47B |
|
$4.91B |
|
$831.70M |
|
-- |
|
$667.10M |
|
$1.50B |
|
$3.41B |
|
$3.41B |
|
$3.41B |
|
100.60M |
|
| Cash Flow Statement Financials | |
$145.80M |
|
$-506.20M |
|
$-86.10M |
|
$721.00M |
|
$274.50M |
|
$-446.50M |
|
$57.20M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.93 |
|
-- |
|
-- |
|
-- |
|
-- |
|
98.31% |
|
23.74% |
|
23.74% |
|
-- |
|
30.30% |
|
24.30% |
|
$136.70M |
|
-- |
|
-- |
|
-- |
|
0.17 |
|
0.21 |
|
1.06 |
|
84.87 |
|
5.81% |
|
5.81% |
|
4.03% |
|
5.81% |
|
$33.87 |
|
$1.32 |
|
$1.41 |
|